The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy

Annals of Surgical Oncology

Volumn 21, Issue 9, 2014, Pages 2911-2919

  Butt, Salma ^a   Butt, Talha ^a   Jirström, Karin ^a,b   Hartman, Linda ^a,b   Amini, Rose Marie ^c   Zhou, Wenjing ^d   Wärnberg, Fredrik ^d   Borgquist, Signe ^a,e  

^a LUND UNIVERSITY   (Sweden)

^b South Swedish Regional   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOPLASM PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HMGCR PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;

ADULT; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; COHORT ANALYSIS; DRUG TARGETING; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TREATMENT RESPONSE; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMISTRY; ENZYMOLOGY; MASTECTOMY; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RADIATION DOSE; SURVIVAL RATE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MASTECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 84906261489     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3708-4     Document Type: Article

References (34)

1. Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010:139-41.
2. Bijker N, Donker M, Wesseling J, den Heeten GJ, Rutgers EJ. Is DCIS breast cancer, and how do I treat it? Curr Treat Options Oncol. 2013;14:75-87.
3. Group SBC. National guidelines for treatment of breast cancer. In: Group SBC, editors. 2010.
4. Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26:1247-52.
5. Correa C, McGale P, Taylor C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010:162-77.
6. Eusebi V, Feudale E, Foschini MP, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994;11:223-35. (Pubitemid 24308083)
7. Warnberg F, Yuen J, Holmberg L. Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet. 2000;355(9205):724-5. (Pubitemid 30107633)
8. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478-88.
9. Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev. 2012;10:CD007847.
10. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272-82. (Pubitemid 47073490)
11. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther. 2008;8:1377-85.
12. Clendening JW, Penn LZ. Targeting tumor cell metabolism with statins. Oncogene. 2012;31:4967-78.
13. Garwood ER, Kumar AS, Baehner FL, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010;119:137-44.
14. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005;5:930-42. (Pubitemid 41766782)
15. Yi M, Meric-Bernstam F, Kuerer HM, et al. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012;30:600-7.
16. Ringberg A, Nordgren H, Thorstensson S, et al. Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast - results from the Swedish randomised trial. Eur J Cancer. 2007;43:291-8. (Pubitemid 46123991)
17. Zhou W, Jirstrom K, Johansson C, et al. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer. 2010;10:653.
18. Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer. 2011;2:232-61.
19. Borgquist S, Jogi A, Ponten F, Ryden L, Brennan DJ, Jirstrom K. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Res. 2008;10:R79.
20. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425-30.
21. Khosravi-Far R, Cox AD, Kato K, Der CJ. Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ. 1992;3:461-9.
22. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med. 2004;229:567-85. (Pubitemid 38878903)
23. Thurnher M, Nussbaumer O, Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res. 2012;18:3524-31.
24. Ma SM, Garcia DE, Redding-Johanson AM, et al. Optimization of a heterologous mevalonate pathway through the use of variant HMG-CoA reductases. Metab Eng. 2011;13:588-97.
25. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-9. (Pubitemid 34219772)
26. Bjarnadottir O, Romero Q, Bendahl PO, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat. 2013;138:499-508.
27. Hamalukic M, Huelsenbeck J, Schad A, Wirtz S, Kaina B, Fritz G. Rac1-regulated endothelial radiation response stimulates extravasation and metastasis that can be blocked by HMG-CoA reductase inhibitors. PLoS One. 2011;6:e26413.
28. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9:10-9. (Pubitemid 36109711)
29. Warnberg F, Nordgren H, Bergh J, Holmberg L. Ductal carcinoma in situ of the breast from a population-defined cohort: an evaluation of new histopathological classification systems. Eur J Cancer. 1999;35:714-20. (Pubitemid 29258139)
30. Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007;451:19-25.
31. Garne JP. Invasive breast cancer in Malmö, 1961-1992 - an epidemiological study. Dissertation, Lund University, Malmö, 1996.
32. Rakovitch E, Nofech-Mozes S, Hanna W, et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer. 2012;106:1160-5.
33. Collins LC, Achacoso N, Haque R, et al. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013;139:453-60.
34. Lacerda Jr L, Liu D, Larson R, et al. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with post-mastectomy radiation (abstract). Cancer Res. 2012;72(24 Suppl):PD03-06.